Interview with the Innovators

PET/CT Imaging in Prostate Cancer Patients

This video interview series features Neal Shore, MD, and Stephen Rowe, MD, PhD, who share their expert insights and perspectives on innovation in the imaging of patients with prostate cancer and the identification of metastases. Topics covered include recent advances in PSMA-directed imaging, the advantages of PET imaging, and the fusion of PET/CT or PET/MRI techniques. In addition, they also discuss the OSPREY and CONDOR clinical studies that led to the approval of PYLARIFY® (piflufolastat F 18) by the FDA in May 2021.
Insights into the Prostate Cancer Imaging Landscape
Dr Steven Rowe shares insights into the prostate cancer imaging landscape and the logistics involved with different radiotracers, with particular emphasis on PYLARIFY® (piflufolastat F 18). Read More ›

Results from the OSPREY Trial in Pre-Prostatectomy Patients
Dr Steven Rowe continues his discussion of PYLARIFY® (piflufolastat F 18) imaging, with a focus on results from the OSPREY clinical trial in pre-prostatectomy patients. Read More ›

PYLARIFY Imaging in High-Risk Prostate Cancer
Dr Steven Rowe expands on the sensitivity and specificity of PYLARIFY® (piflufolastat F 18) imaging in high-risk prostate cancer. Read More ›

Overview of the Molecular Characteristics of PYLARIFY
Dr Steven Rowe details the molecular characteristics of PYLARIFY® (piflufolastat F 18) and the OSPREY and CONDOR pivotal trials, which led to the FDA approval of PYLARIFY®. Read More ›

The Importance of Accurate Staging in Prostate Cancer
Dr Neal Shore emphasizes the importance of accurate staging of prostate cancer and how PYLARIFY® (piflufolastat F 18) can improve treatment decision-making in patients with prostate cancer. Read More ›

Use of PYLARIFY® in Specific Patient Groups
Dr Neal Shore highlights example patient populations that may benefit from improved staging through the use of PYLARIFY® (piflufolastat F 18), a prostate-specific membrane antigen (PSMA)-targeted PET/CT agent. Read More ›

PSMA PET Imaging in Patients with Oligometastatic Prostate Cancer
Dr Neal Shore discusses the importance of PSMA PET imaging across a range of PSA values and how PYLARIFY® (piflufolastat F 18) will affect imaging of patients with oligometastatic prostate cancer. Read More ›

 PYLARIFY and Next-Generation Imaging

PSMA-Targeted Imaging for Prostate Cancer Treatment
Dr Neal Shore discusses the rationale of prostate-specific membrane antigen (PSMA) PET/CT to guide prostate cancer treatment. Read More ›

Overview of Current Imaging Modalities in Prostate Cancer
Dr Neal Shore introduces the current global landscape of various imaging modalities for prostate cancer, including a new prostate-specific membrane antigen (PSMA)-targeted PET/CT agent, PYLARIFY® (piflufolastat F 18). Read More ›

Urology Practice Management logo
Subscribe to Urology Practice Management

Stay up to date with urology news & updates by subscribing to receive the free UPM print publications or e‑Newsletters.

UPM e-Newsletter
UPM print publication